Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H.

J Invest Dermatol. 2007 Jun;127(6):1419-29. Epub 2007 Feb 1.

2.

Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.

Ueyama A, Imura K, Kasai-Yamamoto E, Tai N, Nagira M, Shichijo M, Yasui K.

Clin Exp Dermatol. 2013 Dec;38(8):897-903. doi: 10.1111/ced.12097.

PMID:
24252082
3.

Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.

Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H.

Mol Pharmacol. 2005 Nov;68(5):1254-70. Epub 2005 Aug 11.

4.

Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.

Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP.

J Autoimmun. 2014 Dec;55:63-72. doi: 10.1016/j.jaut.2014.07.003. Epub 2014 Aug 28.

5.

Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.

Hu L, Wang T, Gocke AR, Nath A, Zhang H, Margolick JB, Whartenby KA, Calabresi PA.

PLoS One. 2013;8(1):e54267. doi: 10.1371/journal.pone.0054267. Epub 2013 Jan 30.

6.

Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.

Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, Pennington MW, Hanania NA, Corry DB, Beeton C.

J Biol Chem. 2014 May 2;289(18):12623-32. doi: 10.1074/jbc.M113.517037. Epub 2014 Mar 18.

7.

Sceptridium ternatum attenuates allergic contact dermatitis-like skin lesions by inhibiting T helper 2-type immune responses and inflammatory responses in a mouse model.

Lim D, Kim MK, Jang YP, Kim J.

J Dermatol Sci. 2015 Sep;79(3):288-97. doi: 10.1016/j.jdermsci.2015.06.012. Epub 2015 Jun 26.

PMID:
26150208
8.

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG.

Mol Pharmacol. 2005 Apr;67(4):1369-81. Epub 2005 Jan 21.

9.

Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.

Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA.

J Immunol. 2007 Oct 1;179(7):4563-70.

10.

Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis.

Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R.

J Crohns Colitis. 2014 Nov;8(11):1378-91. doi: 10.1016/j.crohns.2014.04.003. Epub 2014 May 3.

11.

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.

Immunity. 2008 Oct 17;29(4):602-14. doi: 10.1016/j.immuni.2008.07.015. Epub 2008 Oct 2.

12.

Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity.

Weigmann B, Jarman ER, Sudowe S, Bros M, Knop J, Reske-Kunz AB.

J Invest Dermatol. 2006 Jul;126(7):1524-33. Epub 2006 Mar 16.

13.

Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis.

Hyodo T, Oda T, Kikuchi Y, Higashi K, Kushiyama T, Yamamoto K, Yamada M, Suzuki S, Hokari R, Kinoshita M, Seki S, Fujinaka H, Yamamoto T, Miura S, Kumagai H.

Am J Physiol Renal Physiol. 2010 Dec;299(6):F1258-69. doi: 10.1152/ajprenal.00374.2010. Epub 2010 Sep 1.

14.

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.

Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG.

J Clin Invest. 2003 Jun;111(11):1703-13. Erratum in: J Clin Invest. 2003 Jul;112(2):298.

15.

Targeting effector memory T-cells with Kv1.3 blockers.

Wulff H, Pennington M.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):438-45. Review.

PMID:
17659485
16.

Rutin suppresses atopic dermatitis and allergic contact dermatitis.

Choi JK, Kim SH.

Exp Biol Med (Maywood). 2013 Apr;238(4):410-7. doi: 10.1177/1535370213477975.

PMID:
23760007
17.

Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.

Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Béraud E.

J Immunol. 2001 Jan 15;166(2):936-44.

18.

Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice.

Jung SH, Sun X, Ryu WS, Yang BS.

Br J Dermatol. 2013 Jan;168(1):112-9. doi: 10.1111/bjd.12069.

PMID:
23020072
19.

Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG.

FASEB J. 2014 Sep;28(9):3952-64. doi: 10.1096/fj.14-251967. Epub 2014 Jun 2.

20.

Effect of the Kv1.3 voltage-gated potassium channel blocker PAP-1 on the initiation and progress of atherosclerosis in a rat model.

Wu X, Xu R, Cao M, Ruan L, Wang X, Zhang C.

Heart Vessels. 2015 Jan;30(1):108-14. doi: 10.1007/s00380-013-0462-7. Epub 2014 Jan 19.

PMID:
24441938

Supplemental Content

Support Center